[A23-56] Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V
Last updated 07.12.2023
Project no.:
A23-56
Commission:
Commission awarded on 14.06.2023 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Children and adolescents aged 1 year or older with symptomatic chronic heart failure with left ventricular systolic dysfunction
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-09-15.
https://dx.doi.org/10.60584/A23-56_V1.1
| Project no. | Title | Status |
|---|---|---|
| A15-60 | Sacubitril/valsartan - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-103 | Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56 | Commission completed |
Federal Joint Committee (G-BA)
2023-12-07 A G-BA decision was published.